13F reference period
n/a
Security Snapshot
CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share (CERO) Institutional Ownership
CUSIP: 71902K105
13F Institutional Holders and Ownership History from Q4 2021 to Q2 2025
Institutions Reporting
Shares (Excl. Options)
Price
$0.06
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- CERO on Nasdaq
- Shares outstanding
- 5,169,697
- SEC-reported price per share
- $0.06
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- CERO - CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 71902K105.
- 13F reference-period holder data is not available.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder data for the Q2 2026 reference period is not available.
- Available periods remain in the history table; they do not substitute for the headline period.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
71902K105
13F reference period
n/a
13F holders
13D/G owners
2
CIK / CUSIP context first
CERO full holder history
CERO THERAPEUTICS HOLDINGS, INC. SEC filings
CERO THERAPEUTICS HOLDINGS, INC. company facts
CERO THERAPEUTICS HOLDINGS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 71902K105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
CERO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ATWOOD BRIAN G | 9.9% | +46% | $20,472 | +$12,376 | 511,800 | +153% | Brian G. Atwood | 31 Mar 2025 |
| YK Bioventures Opportunities GP I, LLC | 0% | $680 | 17,002 | YK Bioventures Opportunities GP I, LLC | 13 Dec 2024 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
15
Headline period
n/a
Rows shown
1-15 of 15
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q2 | 400 | $24 | +$24 | $0.06 | 1 |
| 2025 Q1 | 0 | $0 | -$956,030 | $0.06 | 0 |
| 2024 Q4 | 13,323,470 | $956,030 | +$580,962 | $0.06 | 19 |
| 2024 Q3 | 3,442,262 | $320,034 | +$160,796 | $0.09 | 17 |
| 2024 Q2 | 1,867,063 | $557,115 | +$77,506 | $0.30 | 14 |
| 2024 Q1 | 1,515,173 | $4,651,346 | -$2,752,548 | $3.07 | 8 |
| 2023 Q4 | 679,166 | $7,488,174 | +$53,470 | $11.00 | 8 |
| 2023 Q3 | 675,140 | $7,332,178 | -$3,254,170 | $10.86 | 9 |
| 2023 Q2 | 976,580 | $10,615,889 | -$2,060,042 | $10.90 | 12 |
| 2023 Q1 | 1,174,274 | $12,543,454 | -$89,026,453 | $10.68 | 15 |
| 2022 Q4 | 9,845,770 | $101,108,715 | -$50,175,043 | $10.27 | 45 |
| 2022 Q3 | 15,151,664 | $152,959,000 | +$5,823,455 | $10.09 | 65 |
| 2022 Q2 | 14,419,635 | $144,538,000 | +$5,286,548 | $10.02 | 54 |
| 2022 Q1 | 13,715,709 | $137,190,000 | +$31,998,515 | $10.00 | 45 |
| 2021 Q4 | 10,510,900 | $104,167,000 | +$90,475,000 | $9.91 | 36 |